Insulin Resistance in Obese Children: What Can Metabolomics and Adipokine Modelling Contribute?

Francisco J Rupérez1, Gabriel Á Martos-Moreno2,3,4,5, David Chamoso-Sánchez1

  • 1Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain.

Nutrients
|November 3, 2020
PubMed

Insights

Childhood obesity presents unique challenges, often leading to insulin resistance. Identifying biomarkers through metabolomics is crucial for predicting metabolic complications in pediatric obesity.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Biomarker Discovery

Background:

  • Childhood obesity is rising, necessitating age-specific definitions and understanding of associated conditions.
  • Metabolic complications, particularly insulin resistance, are common in obese children and adolescents, preceding type 2 diabetes.
  • Identifying predictive biomarkers for these complications is clinically significant.

Purpose of the Study:

  • To review advances in identifying biomarkers for metabolic complications in pediatric obesity.
  • To highlight the role of metabolomics in analyzing metabolic profiles of obese children.
  • To discuss the importance of various metabolomic techniques.

Main Methods:

  • Review of recent studies utilizing metabolomics (targeted and untargeted approaches).
  • Analysis of obesity-induced modifications in adipokine profiles.
  • Examination of different methodologies in metabolomic analysis.

Main Results:

  • Metabolomics shows utility in characterizing metabolic features of pediatric obesity with or without insulin resistance.
  • Adipokine profile analysis is a classic approach for biomarker identification.
  • Various metabolomic techniques offer distinct advantages.

Conclusions:

  • Metabolomics is a valuable tool for understanding metabolic alterations in pediatric obesity.
  • Biomarker discovery is essential for early detection and management of metabolic complications.
  • Further research into metabolomic techniques can enhance clinical utility.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
968
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
89
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
127